Immunic, Inc.

Historical 13F Holders

Symbol
IMUX
CUSIP
4525EP101
All holders as of
Q1 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 4525EP101 since 12/18/2024, largest first.

Filer % of Class Filed
Vivo Opportunity Fund Holdings, L.P. 13G
10.0% 2/20/2026
Event 2/17/2026
Biotechnology Value Fund L P 13D
10.0% 2/20/2026
Event 2/12/2026
Janus Henderson Group PLC 13G 10.0% 12/8/2025
Event 11/28/2025
Adage Capital Management, L.P. 13G/A
10.0% 8/12/2025
Event 6/30/2025
Avidity Partners Management LP 13G
9.9% 4/17/2026
Event 2/17/2026
Trails Edge Capital Partners, LP 13G
8.7% 2/24/2026
Event 2/17/2026
Deep Track Capital, LP 13G
8.7% 3/4/2026
Event 2/17/2026
Nantahala Capital Management, LLC 13G/A
8.2% 2/13/2026
Event 12/31/2025
Aberdeen Group plc 13G/A
6.9% 2/2/2026
Event 12/31/2025
683 Capital Management, LLC 13G/A
5.9% 2/17/2026
Event 12/31/2025
Soleus Capital Master Fund, L.P. 13G
5.5% 2/19/2026
Event 2/17/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (7)
Commodore Capital LP 13G
Amended under CUSIP 4525EP200 on 8/14/2026
9.9% 2/24/2026
Event 2/17/2026
Armistice Capital, LLC 13G/A
4.99% 11/14/2025
Event 9/30/2025
Alyeska Investment Group, L.P. 13G/A
4.9% 5/15/2026
Event 3/31/2026
Vanguard Group Inc 13G/A 4.4% 1/30/2025
Event 12/31/2024
OrbiMed Advisors LLC 13G/A
2.3% 11/16/2026
Event 9/30/2026
Soleus Private Equity Fund III, L.P. 13G/A
1.6% 11/7/2025
Event 9/30/2025
RTW Investments, LP 13G/A
1.1% 5/15/2025
Event 3/31/2025

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q1 76 64.7 M $77.4M
2025 Q4 62 51.3 M $28.3M
2025 Q3 64 42.7 M $37.6M
2025 Q2 59 50.2 M $35.0M
2025 Q1 69 40.5 M $44.1M
2024 Q4 69 51.1 M $51.1M
2024 Q3 63 56.0 M $92.4M
2024 Q2 58 55.8 M $62.1M
2024 Q1 62 57.4 M $75.7M
2023 Q4 53 15.1 M $22.7M
2023 Q3 56 18.4 M $27.0M
2023 Q2 66 20.2 M $50.7M
2023 Q1 63 24.8 M $36.9M
2022 Q4 66 24.9 M $34.8M
2022 Q3 70 17.4 M $55.1M
2022 Q2 78 18.3 M $63.4M
2022 Q1 87 17.7 M $200M
2021 Q4 71 13.7 M $131M
2021 Q3 73 12.9 M $114M
2021 Q2 63 9.44 M $116M
2021 Q1 66 9.30 M $148M
2020 Q4 72 9.73 M $149M
2020 Q3 68 8.55 M $159M
2020 Q2 54 4.21 M $51.0M
2020 Q1 26 2.16 M $13.0M
2019 Q4 25 2.14 M $20.7M
2019 Q3 28 1.50 M $15.0M
2019 Q2 26 1.54 M $17.6M